Compare JACK & SABS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | JACK | SABS |
|---|---|---|
| Founded | 1951 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Restaurants | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 326.6M | 344.8M |
| IPO Year | 1994 | 2020 |
| Metric | JACK | SABS |
|---|---|---|
| Price | $12.79 | $2.99 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 16 | 11 |
| Target Price | ★ $19.92 | $11.64 |
| AVG Volume (30 Days) | 486.4K | ★ 637.7K |
| Earning Date | 11-18-2026 | 11-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 78.53 |
| EPS | ★ 1.44 | N/A |
| Revenue | ★ $1,465,314,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $0.98 | N/A |
| P/E Ratio | $8.65 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $8.92 | $2.10 |
| 52 Week High | $23.86 | $5.15 |
| Indicator | JACK | SABS |
|---|---|---|
| Relative Strength Index (RSI) | 38.40 | 34.77 |
| Support Level | $11.92 | N/A |
| Resistance Level | $14.02 | $3.99 |
| Average True Range (ATR) | 0.57 | 0.20 |
| MACD | 0.03 | -0.03 |
| Stochastic Oscillator | 33.74 | 28.12 |
Jack In The Box Inc operates quick-service restaurants and fast-casual restaurants across various states in the United States of America. Its core business includes the Jack in the Box hamburger chain, known for a broad menu that features hamburgers, tacos, sandwiches, salads, and breakfast items. The company also operates the Del Taco brand, which offers a variety of both Mexican and American favorites such as burritos and fries. These foods are available with the option of customization as per customer requirements. The company also offers catering and delivery services to its customers. Jack in the Box and Del Taco restaurant brands are the two reportable operating segments, of which, Jack in the Box generates maximum revenue for the company.
SAB Biotherapeutics Inc is a clinical-stage biopharmaceutical company focused on developing multi-specific, high-potency, human immunoglobulin G (hIgG) to treat and prevent immune and autoimmune disorders. The company's lead product candidate, SAB-142, targets autoimmune Type 1 Diabetes (T1D) with a disease-modifying therapeutic approach that aims to change the T1D treatment paradigm by delaying onset and potentially preventing disease progression of Stage 3 T1D patients. It is focused on developing product candidates for disease targets where a differentiated approach has the greatest potential to be either first-in-class against novel targets against complex targets to treat diseases, including type 1 diabetes (T1D) and other autoimmune disorders.